Lafayette Richard A, Charu Vivek, Glassock Richard J
Stanford Glomerular Disease Center, Stanford University, Stanford, CA, USA.
Department of Pathology, Stanford University, Stanford, CA, USA.
Adv Ther. 2025 May;42(5):2003-2014. doi: 10.1007/s12325-025-03167-x. Epub 2025 Mar 27.
Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) is a rare pattern of kidney injury and a progressive nephropathy characterized by the glomerular deposition of immune complexes and complement proteins. The IC-MPGN pattern of injury exhibits a membranoproliferative glomerulonephritis appearance by light microscopy and occurs secondary to various conditions or, more rarely, idiopathically, when no underlying etiology can be determined. Kidney biopsy is the only method for identifying IC-MPGN, distinguishing between IC-MPGN and complement 3 glomerulopathy (C3G), and for providing critical pathologic insights that guide further clinical evaluation for underlying etiologies and inform patient management. Given the progressive nature of IC-MPGN, it is crucial to identify patients early and to define the underlying pathophysiology for timely and appropriate treatment. However, several challenges remain in the accurate interpretation of kidney biopsy specimens and the effective treatment of idiopathic disease. In this commentary, two nephrologists and a nephropathologist review best practices in the clinical and histopathologic evaluation of IC-MPGN and discuss the central role of kidney biopsy in the differentiation of IC-MPGN and C3G. The challenges and considerations discussed are explored through an illustrative case of idiopathic disease, drawn from the authors' clinical experiences. Finally, remaining unmet needs are highlighted, and future perspectives on targeted treatments under investigation for patients with idiopathic IC-MPGN are provided.
免疫复合物介导的膜增生性肾小球肾炎(IC-MPGN)是一种罕见的肾损伤模式,是一种进行性肾病,其特征为免疫复合物和补体蛋白在肾小球沉积。IC-MPGN损伤模式在光学显微镜下呈现膜增生性肾小球肾炎表现,继发于各种情况,或更罕见地,在无法确定潜在病因时为特发性。肾活检是识别IC-MPGN、区分IC-MPGN和补体3肾小球病(C3G)的唯一方法,也是提供关键病理见解以指导对潜在病因进行进一步临床评估并为患者管理提供依据的唯一方法。鉴于IC-MPGN的进行性本质,早期识别患者并确定潜在病理生理学以进行及时和适当的治疗至关重要。然而,在准确解读肾活检标本和有效治疗特发性疾病方面仍存在一些挑战。在这篇评论中,两位肾脏病学家和一位肾病理学家回顾了IC-MPGN临床和组织病理学评估的最佳实践,并讨论了肾活检在区分IC-MPGN和C3G中的核心作用。通过一个来自作者临床经验的特发性疾病实例探讨了所讨论的挑战和注意事项。最后,强调了尚未满足的需求,并提供了针对特发性IC-MPGN患者正在研究的靶向治疗的未来展望。